FXYD5 and cancer: We also provide an explanation and potential solution to the failure of SLC9 specific inhibitors in the treatment of cancer metastasis, and confirm current studies53–55 suggesting that dysadherin is a potential therapeutic target for cancer associated cellular transformations.